资讯

GlobalData on MSN5 天
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...
Contract Pharma5 天
Rznomics & Eli Lilly Enter Global Licensing Agreement
Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy ...
Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...
Pharmaceutical Technology6 天
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics
Credit: Scott Olson/Getty Images News via Getty Images. Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics ...
Investing Snacks2 天
Lilly Hears Opportunity in $1.3B RNA Therapy Deal
Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...
PipelineReview.com5 天
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
SEONGNAM, South Korea I May 15, 2025 I Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global ...
PR Newswire6 天
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and commercialize ...